RESEARCH TRIANGLE PARK, N.C.
March 4, 2011 /PRNewswire/ -- Grifols
S.A. (GRF.MC) and Talecris Biotherapeutics Holdings Corp. (Nasdaq:
TLCR) today announced that the outside date under their merger
agreement for closing their pending merger transaction has been
extended to June 30, 2011 (from
March 6, 2011). Grifols has extended
the financing and financing commitments from its lenders to
June 30, as well. Grifols is
continuing to work with the U.S. Federal Trade Commission to obtain
its clearance of the proposed transaction. As previously disclosed,
Grifols has agreed with FTC not to close the merger transaction
without providing to the FTC at least thirty days advanced
notice.
About Grifols
Grifols is a Spanish holding company, specializing in the
hospital-pharmaceutical sector, and with a presence in over 90
countries. Since May 2006 it has been
listed on the Spanish Continuous Market, and it is included in the
Ibex-35. Grifols is the leading European plasma products company,
and the fourth-largest producer in the world. The company plans to
strengthen its position within the industry as a vertically
integrated company, on the basis of its ongoing investment program.
In terms of raw material, Grifols has secure plasma supplies from
its network of 80 plasmapheresis centers in the United States, while its production plants
in Barcelona (Spain) and Los
Angeles (United States)
ensure that it has the fractionation capacity to satisfy rising
demand. In addition, the company has implemented an ambitious
investment plan to enable it to deliver sustained growth over the
next 8 to 10 years.
About Talecris Biotherapeutics: Inspiration.
Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and
biotechnology company that discovers, develops and produces
critical care treatments for people with life-threatening disorders
in a variety of therapeutic areas including immunology,
pulmonology, neurology and hemostasis. For more information, please
visit: www.talecris.com
SOURCE Talecris Biotherapeutics, Inc.